An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227). (4th November 2015) - Hellmann, Matthew; Ramalingam, Suresh; Reck, Martin; O'Byrne, Ken; Paz-Ares, Luis; Harbison, Christopher T; Bhagavatheeswaran, Prabhu; Nathan, Faith; Brahmer, Julie